International Biotechnology Trust has announced results for the year ended 31 August 2015. Over this period the NAV return was 48.2% which compares very favourably to the return on IBT’s benchmark, NASDAQ Biotechnology Index, which returned 33.6%. The share price did even better as the discount narrowed from 20.5% to 6.0% and shareholders got a return […]
International Biotech is part owner of an unquoted UK biotech stock, Convergence Pharmaceuticals, that is being acquired by Biogen Idec. At the purchase price of $675m, International Biotech’s stake is worth £6.8m. This compares to the £442,000 valuation of the company in International Biotech’s accounts. For now though International Biotech is writing up the value […]
IBT : International Biotech fee cut International Biotechnology Trust has announced its results for the year that ended on 31 August 2014. They show the net asset value rising by 26.4% which lags the return on the NASDAQ Biotechnology Index which returned 33.2% in Sterling terms. Shareholders were impacted by a widening of IBT’s discount […]
The healthcare and biotechnology sector has some natural tailwinds: ageing populations, rising emerging market wealth, innovation and rising healthcare utilisation. However, while pharmaceutical companies have been stable, biotechnology has been hit by poor sentiment and rising interest rates. Nevertheless, there are signs of recovery. The sector is diverse. Funds such as Polar Capital Global Healthcare […]
Whilst the ongoing conflicts in Ukraine and the Middle East have intensified, economic recovery in the US continues, with a rise in the S&P Global US composite PMI output index, tracking improvements in the outlook for both manufacturing and services. With May’s reading of 54.4, the index reached its highest level since April 2022 (figures […]
May 2024 Monthly | Investment companies Kindly sponsored by abrdn Winners and losers in April 2024 Chinese shares lead the list of best performers in April, although they remain deeply depressed with the world’s second largest economy still struggling with a range of long-standing structural issues. So far, the People’s Bank of China has been […]
In QuotedData’s morning briefing 8 May 2023: International Biotechnology Trust (IBT) announced its results for the six month period ended 29 February 2024. The company saw a 11.2% NAV total return per share, substantially outperforming the Reference Index which rose by 8.2%. Notable contributions came from Vera Therapeutics, an autoimmune company which is a top […]
Polar Capital Global Healthcare Investment Companies | Initiation | 5 March 2024 Healthy returns and a rosy outlook Polar Capital Global Healthcare (PCGH) is, as we show on page 16, the leading performer within its peer group over the long term. Its managers’ high-conviction approach and good stock-picking skills have helped it navigate a period […]
Polar Capital Global Healthcare Investment companies | Initiation | 5 March 2024 Healthy returns and a rosy outlook Polar Capital Global Healthcare (PCGH) is, as we show on page 16, the leading performer within its peer group over the long term. Its managers’ feel that their high-conviction approach and stock-picking skills have helped the trust […]
Polar Capital Global Healthcare Investment companies | Initiation | 5 March 2024 Healthy returns and a rosy outlook Polar Capital Global Healthcare (PCGH) is, as we show on page 17, the leading performer within its peer group over the long term. Its managers’ high-conviction approach and good stock-picking skills have helped it navigate a period […]
